Safety and Efficacy of Microbial Ecosystem Therapeutic-2 (MET-2) in Patients With Ulcerative Colitis (UC)

NCT03832400 | Completed Phase 1

• 1 other identifier: MET-2-201
• Study Type: interventional
• Target: 11
• Locations: 1 country
• Sites: 1

Brief Summary

To define the parameters for dose-dependent engraftment of MET-2 commensal bacteria for the treatment of mild to moderate ulcerative colitis

Conditions

Ulcerative Colitis

Outcome Measures

Primary Outcomes (1)

• Gut Microbiome restoration

  Microbiologic assessment of fecal deoxyribonucleic acid (DNA) samples will be obtained before, during and after treatment to quantify the change in microbial alpha diversity using statistical methods such as Shannon Diversity Index and Microbiome Health Index

  Baseline vs. day 42

Secondary Outcomes (2)

• Assessment of mucosal healing

  Baseline vs. Day 42

• Inflammatory Bowel Disease Questionnaire

  Baseline vs. Day 42

Study Arms (3)

MET-2 20 g

EXPERIMENTAL

Subjects will be given a once-daily loading dose of 5 grams (g) of MET-2 in the form of 10 MET-2 capsules orally for the first 4 days. For the following 10 days, patients will take 1.5 g MET-2 in the form of three MET-2 capsules taken once-daily

Biological: MET-2

MET-2 40 g

EXPERIMENTAL

Subjects will be given a once-daily loading dose of 10 g of MET-2 in the form of 20 MET-2 capsules orally for the first 4 days. For the following 10 days, subjects will take 1.5 g MET-2 in the form of three MET-2 capsules taken once daily

Biological: MET-2

Placebo oral capsule

PLACEBO COMPARATOR

Subjects receive 10 placebo capsules that are identical in appearance to the MET-2 capsules

Drug: Placebo oral capsule

Interventions

MET-2 BIOLOGICAL

MET-2 is a defined consortium of human commensal bacteria derived from a healthy donor, which has the full metabolic functional capacity of fecal microbiota.

MET-2 20 g; MET-2 40 g

Placebo oral capsule DRUG

Placebo oral capsule which is identical to the MET-2 capsules.

Placebo oral capsule

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Mild to Moderate UC.
• ≥ 18 years old.
• Able to provide informed consent, or have a caregiver able to provide consent.
• Subjects must have a documented diagnosis (radiologic or endoscopic with histology) of UC for \>3 months before screening. The following must be available in each subject's source documentation:
• A biopsy report to confirm the histological diagnosis
• A report documenting disease duration and medication history prior to study colonoscopy
• Subjects receiving any treatment(s) forUC are eligible provided they are anticipated to be on a stable dose for the duration of the study period and have been on therapy prior to the randomization visit for the following amount of time:
• Prednisone - 4 weeks; Budesonide - 4 weeks; 5-aminosalicylic acid (5-ASA) containing products - 4 weeks; Thiopurine analogs (azathioprine, 6-mercaptopurine) - 12 weeks; Biologic therapy (infliximab, adalimumab, vedolizumab) - 12 weeks; Tofacitinib - 8 weeks.
• No change in dose is permitted for the following time period prior to the randomization visit:
• Prednisone - 2 weeks; Budesonide - 4 weeks; 5-ASA containing products - 4 weeks; Thiopurine analogs (azathioprine, 6-mercaptopurine) - 6 weeks; Biologic therapy (infliximab, adalimumab, vedolizumab) - 6 weeks; Tofacitinib - 4 weeks.
• Subjects are males or nonpregnant, nonlactating females who, if sexually active, agree to comply with the contraceptive requirements of the protocol, or females of nonchildbearing potential. Males and females of reproductive potential who are sexually active must agree to use acceptable contraception for the duration of the study.
• Willing to participate in follow up as part of the study.

You may not qualify if:

• Ulcerative colitis with disease limited to only the distal rectum (\<5cm from dentate line).
• Subjects with indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, or clinical/histologic findings suggestive of Crohn's disease will be excluded.
• Subjects with colonic dysplasia or neoplasia. (Subjects with prior history of adenomatous polyps will be eligible if the polyps have been completely removed).
• Subjects with toxic megacolon or hospitalized for ulcerative colitis.
• Subjects with colonic stricture, past medical history of colonic resection, a history of bowel surgery within 6 months before screening, or who are likely to require surgery for UC during the treatment period.
• Use of antibiotics within 6 weeks of randomization visit.
• Allergy to vancomycin.
• Elective surgery that will require preoperative antibiotics planned within 3 months of enrolment.
• Pregnant or planning to get pregnant in the next 6 months.
• Any condition for which, in the opinion of the investigator, the subject should be excluded from the study.

Sponsors & Collaborators

• NuBiyota: lead

Study Sites (1)

Mount Sinai Hospital

Toronto, Ontario, M5G1X5, Canada

Location

MeSH Terms

Conditions

Colitis, Ulcerative

Condition Hierarchy (Ancestors)

Colitis; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Inflammatory Bowel Diseases; Colonic Diseases; Intestinal Diseases

Study Officials

• Allan H Steinhart, MD

  MOUNT SINAI HOSPITAL

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: The assessor will be blinded as to which dosing arm the subjects are assigned.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: This is a Phase 1b, placebo-controlled, multiple dose pilot study.

Study Record Dates

• First Submitted: November 21, 2018
• First Posted: February 6, 2019
• Study Start: February 4, 2019
• Primary Completion: March 1, 2020
• Study Completion: March 1, 2020
• Last Updated: May 3, 2021

Record last verified: 2020-08

Locations

CA (1)